The present invention relates to treating malignancies such as tumors or cancers by orally administering lyophilized compositions comprising arsenic to a subject in such need. Malignancies include various hematological malignancies, such as acute myeloid leukemia (AML) including acute promyelocytic leukemia (APL), myelodysplastic syndrome (MDS), multiple myeloma (MM) and lymphomas and solid tumors including glioblastoma multiforme and breast cancer. Arsenic treatment has shown great promise in the treatment of several cancers but requires daily intravenous (IV) administration. This invention relates to a novel formulation comprising a lyophilized compositions comprising arsenic. As a result, the formulation facilitates a systemic bioavailability comparable to that of intravenous (IV) administration of arsenic trioxide currently practiced. The present invention also relates to a method for lyophilizing the arsenic trioxide, preparing the oral formulation comprising lyophilized compositions comprising arsenic, and a method for treating a subject with malignancies using the oral formulation.本發明係關於藉由向有需要之個體經口投與含砷冷凍乾燥組合物治療惡性病(諸如腫瘤或癌症)。惡性病包括各種血液惡性病，諸如急性骨髓性白血病(AML)(包括急性前髓細胞性白血病(APL))、骨髓發育不良症候群(MDS)、多發性骨髓瘤(MM)及淋巴瘤；及實體腫瘤，包括多形性膠質母細胞瘤及乳癌。砷治療已在數種癌症治療中顯示極大前景，但需要每日靜脈內(IV)投與。本發明係關於一種新穎調配物，其包含含砷冷凍乾燥組合物。因此，該調配物促進全身生物可用性與目前實施的三氧化二砷的靜脈內(IV)投與相當。本發明亦關於一種用於冷凍乾燥三氧化二砷、製備包含含砷冷凍乾燥組合物之經口調配物的方法，及一種使用該經口調配物治療患有惡性病之個體的方法。
